Risk factors for the development of recurrent atrial fibrillation: Role of pacing and clinical variables

Sharon C. Reimold, Gervasio A. Lamas, Catherine O. Cantillon, Elliott M. Antman

Research output: Contribution to journalArticle

36 Citations (Scopus)

Abstract

Atrial fibrillation recurs in many patients treated with antiarrhythmic therapy to maintain sinus rhythm. From March 1985 to August 1991, 214 patients with recurrent symptomatic chronic or paroxysmal atrial fibrillation for which conventional antiarrhythmic agents had failed were treated with propafenone or sotalol. Baseline demographic data including the presence of pacing therapy were collected. Life-table estimates of the duration of freedom from atrial fibrillation were constructed on the basis of pacemaker status. Of 214 patients, 26 (12.1 %) had pacing therapy. Patients with dual-chamber pacing were more likely to remain in sinus rhythm at 6 months (80%) than were patients with ventricular pacing (40%) or patients without pacing therapy (55%) (p = 0.002). A Cox univariate regression analysis demonstrated that dual-chamber pacing in contrast to ventricular pacing or no pacing was associated with a lower risk of recurrent atrial fibrillation. Clinical parameters such as age, gender, left atrial size, fibrillation pattern, drug assignment, ejection fraction, and underlying cardiac disease did not alter the risk of recurrent atrial fibrillation. Dual-chamber pacing was associated with a decreased likelihood of recurrent atrial fibrillation even after adjustment for other clinical covariates in a multivariate model (p = 0.04). In patients with recurrent atrial fibrillation treated with propafenone or sotalol, dual-chamber pacing improved maintenance of sinus rhythm.

Original languageEnglish (US)
Pages (from-to)1127-1132
Number of pages6
JournalAmerican Heart Journal
Volume129
Issue number6
DOIs
StatePublished - 1995

Fingerprint

Atrial Fibrillation
Propafenone
Sotalol
Life Tables
Therapeutics
Heart Diseases
Regression Analysis
Maintenance
Demography
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Risk factors for the development of recurrent atrial fibrillation : Role of pacing and clinical variables. / Reimold, Sharon C.; Lamas, Gervasio A.; Cantillon, Catherine O.; Antman, Elliott M.

In: American Heart Journal, Vol. 129, No. 6, 1995, p. 1127-1132.

Research output: Contribution to journalArticle

Reimold, Sharon C. ; Lamas, Gervasio A. ; Cantillon, Catherine O. ; Antman, Elliott M. / Risk factors for the development of recurrent atrial fibrillation : Role of pacing and clinical variables. In: American Heart Journal. 1995 ; Vol. 129, No. 6. pp. 1127-1132.
@article{3a7799c142b64f26be559b74a46a1181,
title = "Risk factors for the development of recurrent atrial fibrillation: Role of pacing and clinical variables",
abstract = "Atrial fibrillation recurs in many patients treated with antiarrhythmic therapy to maintain sinus rhythm. From March 1985 to August 1991, 214 patients with recurrent symptomatic chronic or paroxysmal atrial fibrillation for which conventional antiarrhythmic agents had failed were treated with propafenone or sotalol. Baseline demographic data including the presence of pacing therapy were collected. Life-table estimates of the duration of freedom from atrial fibrillation were constructed on the basis of pacemaker status. Of 214 patients, 26 (12.1 {\%}) had pacing therapy. Patients with dual-chamber pacing were more likely to remain in sinus rhythm at 6 months (80{\%}) than were patients with ventricular pacing (40{\%}) or patients without pacing therapy (55{\%}) (p = 0.002). A Cox univariate regression analysis demonstrated that dual-chamber pacing in contrast to ventricular pacing or no pacing was associated with a lower risk of recurrent atrial fibrillation. Clinical parameters such as age, gender, left atrial size, fibrillation pattern, drug assignment, ejection fraction, and underlying cardiac disease did not alter the risk of recurrent atrial fibrillation. Dual-chamber pacing was associated with a decreased likelihood of recurrent atrial fibrillation even after adjustment for other clinical covariates in a multivariate model (p = 0.04). In patients with recurrent atrial fibrillation treated with propafenone or sotalol, dual-chamber pacing improved maintenance of sinus rhythm.",
author = "Reimold, {Sharon C.} and Lamas, {Gervasio A.} and Cantillon, {Catherine O.} and Antman, {Elliott M.}",
year = "1995",
doi = "10.1016/0002-8703(95)90393-3",
language = "English (US)",
volume = "129",
pages = "1127--1132",
journal = "American Heart Journal",
issn = "0002-8703",
publisher = "Mosby Inc.",
number = "6",

}

TY - JOUR

T1 - Risk factors for the development of recurrent atrial fibrillation

T2 - Role of pacing and clinical variables

AU - Reimold, Sharon C.

AU - Lamas, Gervasio A.

AU - Cantillon, Catherine O.

AU - Antman, Elliott M.

PY - 1995

Y1 - 1995

N2 - Atrial fibrillation recurs in many patients treated with antiarrhythmic therapy to maintain sinus rhythm. From March 1985 to August 1991, 214 patients with recurrent symptomatic chronic or paroxysmal atrial fibrillation for which conventional antiarrhythmic agents had failed were treated with propafenone or sotalol. Baseline demographic data including the presence of pacing therapy were collected. Life-table estimates of the duration of freedom from atrial fibrillation were constructed on the basis of pacemaker status. Of 214 patients, 26 (12.1 %) had pacing therapy. Patients with dual-chamber pacing were more likely to remain in sinus rhythm at 6 months (80%) than were patients with ventricular pacing (40%) or patients without pacing therapy (55%) (p = 0.002). A Cox univariate regression analysis demonstrated that dual-chamber pacing in contrast to ventricular pacing or no pacing was associated with a lower risk of recurrent atrial fibrillation. Clinical parameters such as age, gender, left atrial size, fibrillation pattern, drug assignment, ejection fraction, and underlying cardiac disease did not alter the risk of recurrent atrial fibrillation. Dual-chamber pacing was associated with a decreased likelihood of recurrent atrial fibrillation even after adjustment for other clinical covariates in a multivariate model (p = 0.04). In patients with recurrent atrial fibrillation treated with propafenone or sotalol, dual-chamber pacing improved maintenance of sinus rhythm.

AB - Atrial fibrillation recurs in many patients treated with antiarrhythmic therapy to maintain sinus rhythm. From March 1985 to August 1991, 214 patients with recurrent symptomatic chronic or paroxysmal atrial fibrillation for which conventional antiarrhythmic agents had failed were treated with propafenone or sotalol. Baseline demographic data including the presence of pacing therapy were collected. Life-table estimates of the duration of freedom from atrial fibrillation were constructed on the basis of pacemaker status. Of 214 patients, 26 (12.1 %) had pacing therapy. Patients with dual-chamber pacing were more likely to remain in sinus rhythm at 6 months (80%) than were patients with ventricular pacing (40%) or patients without pacing therapy (55%) (p = 0.002). A Cox univariate regression analysis demonstrated that dual-chamber pacing in contrast to ventricular pacing or no pacing was associated with a lower risk of recurrent atrial fibrillation. Clinical parameters such as age, gender, left atrial size, fibrillation pattern, drug assignment, ejection fraction, and underlying cardiac disease did not alter the risk of recurrent atrial fibrillation. Dual-chamber pacing was associated with a decreased likelihood of recurrent atrial fibrillation even after adjustment for other clinical covariates in a multivariate model (p = 0.04). In patients with recurrent atrial fibrillation treated with propafenone or sotalol, dual-chamber pacing improved maintenance of sinus rhythm.

UR - http://www.scopus.com/inward/record.url?scp=0029019967&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029019967&partnerID=8YFLogxK

U2 - 10.1016/0002-8703(95)90393-3

DO - 10.1016/0002-8703(95)90393-3

M3 - Article

C2 - 7754943

AN - SCOPUS:0029019967

VL - 129

SP - 1127

EP - 1132

JO - American Heart Journal

JF - American Heart Journal

SN - 0002-8703

IS - 6

ER -